| |

How to Write an Investor Ready Biotech Startup Business Plan

Most founders only learn how to write a business plan for biotech startup after one painful meeting with an investor. You might have groundbreaking science, but investors will quickly lose interest if your plan reads like a lab report. At the end of the day, venture capitalists want two simple answers upfront: how much cash you need, and what scientific milestone that money will prove. This guide walks you through building an investor-ready biotech business plan, step by step.

What this article covers

  • Business plan vs pitch deck
  • The 8 sections every plan need, each with a tip
  • Market size and use of proceeds examples
  • Common mistakes and 6 founder questions

Biotech Business Plan vs Life Science Startup Pitch Deck

A business plan is a long document of 20 to 30 pages that explains your science and your money plan in detail. A pitch deck is a short slide set that makes investors curious. Write the business plan first, because it forces you to answer the hard questions. Then cut it into slides.

A Mondaq guide to biotech business plans says a fund that likes your pitch will ask for a full business plan of about 20 to 30 pages and then check every claim. Keep a two-page summary ready for the first email.

💡Tip: Write the business plan for biotechnology startup before the pitch deck. Slides hide gaps. A plan shows them.

How to Write a Biotech Business Plan: The 8 Key Pillars

A biotech business plan has eight parts: executive summary, technology and pipeline, intellectual property, market, regulatory and clinical plan, manufacturing, team, and financials. Each part must link to value, meaning something that makes your company worth more. Write the executive summary in the last, even though it comes first.

1. Executive Summary and the Unmet Need

The executive summary for a biotech business plan has a purpose to make investors want to read the full plan. Keep it to one page. Open with the patient problem in numbers, i.e. how many people have the disease, what current treatment fails to do, and what that costs each year. Describe your solution in two sentences and say how it beats the standard of care, such as higher efficacy or fewer side effects.

Finish with the funding requirements with milestone based and expected timeline. Law firm Morgan Lewis advises link the amount you raise to a specific milestone, so investors see how far their money goes.

A biotech startup’s funding strategy must be directly aligned with its development stage, as capital requirements and risk profiles shift dramatically over time.

For Instance, Early stages (Idea & Lab Discovery) rely heavily on non-dilutive grants, university tech transfer funds, and bootstrapping to build initial proof-of-concept. As the startup progresses through Pre-Clinical and Clinical Trials, the strategy transitions toward deep-tech VCs, specialized healthcare funds, and strategic pharma partnerships to cover heavy R&D and validation costs.

💡Tip: Write executive summary page in last. Then ask a stranger to read it once whether it make sense or not.

2. Technology Platform and Product Pipeline

Start with how your drug works. Scientists call this the mechanism of action. Explain it the way you would to a friend who is not a scientist. Then show proof. Lab tests in cells (in vitro) show whether the idea works on a small scale. Tests in animals (in vivo) show how it works in a living body. Next, explain to investors what you are building, a platform or a single asset. A platform is one technology that can make many drugs, such as mRNA tools. A single asset is one lead drug that you take all the way to approval.

Add a pipeline chart with a bar for each program, from Discovery through Phase 3. Phase 2 is where programs fail most often: in a BIO study of 2006 to 2015, only 30.7% of candidates moved from Phase 2 to Phase 3.

💡Tip: Be honest and proactive about your company’s vulnerabilities instead of trying to hide them, because smart investors will uncover them during their evaluation regardless.

3. Intellectual Property Strategy

The IP section breaks down your patent holdings, pending filings, licensing agreements, trade secrets, and legal Freedom to Operate (FTO) analysis.

Science without strong patent protection has zero commercial value. VCs check this section to confirm that competitors cannot copy your discovery or block your market entry.

  • Patent Estate: List patent application numbers, jurisdictions, filing dates, and expected expiration years.
  • Freedom to Operate (FTO): Include a legal assessment confirming your product does not infringe on existing third-party patents.
  • Exclusivity & Trade Secrets: Add trade secrets, such as special biological assays, cell lines, formulation know-how, and custom manufacturing processes. For a rare disease, add orphan status. The FDA Orphan Drug Designation grants this status for conditions that affect fewer than 200,000 people in the US, bringing seven years of market exclusivity after approval.

💡Tip: If you licensed technology from an academic university, clearly state royalty terms, sublicensing rights, and milestone obligations alongside your proprietary trade secrets.

4. Market Opportunity and Commercial Strategy

This section proves how big your business can grow. It calculates your market size by counting real patients, details your target product specifications, compares your asset to existing competitors, and explains how your biotech startup will make money before full market launch.

Read: Biotechnology Market Research Report by Excel Business Resource

Do not use top-down guesses like “we will capture 1% of the global cancer market.” Venture capital investors reject those claims instantly. Instead, build your numbers from the ground up using real patient counts and clear medical eligibility rules.

How to Calculate Your Market Size (Bottom-Up Math)

Break your target market into three simple steps based on patient populations:

  1. Total Addressable Market (TAM): The total number of people diagnosed with the disease.
  2. Serviceable Addressable Market (SAM): The smaller group of patients who actually qualify for your specific treatment.
  3. Serviceable Obtainable Market (SOM): The realistic portion of patients you can treat based on your team size, budget, and sales reach.
Bottom-Up Math Example 1: Targeted Biomarker Patients
  • Diagnosed Patients: 1,000,000 total patients with the disease.
  • Target Marker: Only 15% carry the specific genetic marker = 150,000 patients.
  • Second-Line Need: 40% of those need a new treatment after their first medicine stops working = 60,000 eligible patients (SAM).
  • Expected Price: $60,000 per patient per year.
  • SAM Value: 60,000 patients × $60,000/year = $3.6 Billion total market.
  • Obtainable Revenue (SOM): Winning a 10% market share yields $360 Million in peak yearly sales.
Bottom-Up Math Example 2: Refractory Multiple Myeloma
  • Target Disease: Refractory Multiple Myeloma.
  • US Patient Count: According to patient data tracked by the American Cancer Society, around 35,000 people are diagnosed annually in the US (TAM).
  • Eligible Subpopulation: 40% meet your specific clinical profile = 14,000 patients (SAM).
  • Expected Price: $150,000 per patient per year.
  • SAM Value: 14,000 patients × $150,000/year = $2.1 Billion total market.

Target Product Profile (TPP)

Your Target Product Profile (TPP) is a simple checklist that describes how your drug works, how patients take it, and how safe it needs to be. It serves as a clear goal for your lab team and early licensing partners.

  • Target Condition: Second-line treatment for solid tumors.
  • How Patients Take It: Once-weekly injection or once-monthly shot under the skin.
  • Efficacy Goal: Aiming for a 25% or higher tumor response rate and extending patient survival by 3 to 6 months compared to current drugs.
  • Safety Goal: Low side effects, with severe reactions happening in less than 5% to 15% of patients.
  • Storage: Stable at standard refrigeration temperatures so doctors can store it easily.

Understanding these revenue streams makes it easier to figure out how biotech startups make money long before commercial launches. Founders should also learn how to forecast revenue for biotech startups in Excel so their financial models accurately capture these multi-year licensing deals and milestone timelines.

💡Tip: Always provide a clear source for every patient statistic, drug pricing estimate, and clinical benchmark you list. Investors check each source carefully during financial and scientific due diligence.

5.    Regulatory Pathway and Clinical Strategy

This section defines your exact roadmap for getting approval from agencies like the FDA (USA) and EMA (Europe). It lists your specific submission paths, dates, special speedy designations, clinical trial designs, and quality standards.

A strong regulatory strategy for biotech startups (FDA/EMA) names your exact regulatory path and projected target dates. For standard drug candidates, this means moving from an Investigational New Drug (IND) application to a New Drug Application (NDA) or Biologics License Application (BLA). If you build a medical device, you will likely follow a 510(k) or Premarket Approval (PMA) route.

Your plan must also list special designations that can speed up review timelines:

  • Fast Track Designation: You can apply for this based on strong preclinical lab data showing your asset meets an unmet medical need.
  • Breakthrough Therapy Designation: Requires early clinical evidence showing significant improvement over existing treatments.
  • European Union (EMA) Approval Track: European markets require a separate submission track because EMA rules differ from FDA guidelines. Outlining a standalone EMA approval path proves your global strategy to investors.

Clinical Trial Design & HHS Benchmarks

Your clinical trial roadmap must show specific goals, patient numbers, and estimated timelines for each phase. According to data analysis by the US Department of Health and Human Services, multi-year clinical phases average the following metrics per single trial:

  • Phase 1 (Safety & Dosing): Lasts an average of 27.8 months with around 51 patients.
  • Phase 2 (Efficacy & Side Effects): Lasts an average of 34.0 months with around 235 patients.
  • Phase 3 (Pivotal Efficacy Proof): Lasts an average of 38.0 months with around 630 patients.

Quality & Compliance Framework

Maintain strict compliance standards across all operating stages:

  • Good Laboratory Practice (GLP): Covers all preclinical safety and laboratory testing.
  • Good Clinical Practice (GCP): Governs ethical standards and protocols for human clinical trials.
  • Good Manufacturing Practice (GMP): Ensures clinical supplies and batches meet strict regulatory purity standards.

💡Tip: Request a Pre-IND meeting with the FDA well before filing your final IND application. Include their written feedback in your business plan to prove to investors that you are directly incorporating regulator guidance.

6. Manufacturing and Operations Strategy

This section details how you produce your drug candidate and run your lab operations. It explains Chemistry, Manufacturing, and Controls (CMC), details why you outsource work to contract partners, and budgets for hidden operational costs.

Investors want to see that you can manufacture your drug reliably while keeping fixed overhead low.

What Is CMC and Why Does It Matter?

CMC stands for Chemistry, Manufacturing, and Controls. In plain terms, CMC is your step-by-step recipe and quality guide. It proves to regulators like the FDA that:

  • Every batch of your drug is made using the exact same process.
  • The drug stays safe, pure, and stable over time.

Outsourcing Strategy: Build vs. Buy

Building your own manufacturing plant and hiring full-time lab staff costs millions of dollars. Early-stage startups keep fixed costs low by outsourcing work to specialized partner companies:

  • Contract Development and Manufacturing Organizations (CDMOs): You pay CDMOs to manufacture your drug batches, handle scale-up logistics, and run stability testing.
  • Contract Research Organizations (CROs): You hire CROs to manage patient recruitment, hospital sites, and data collection for your clinical trials.

In your business plan, list exactly which tasks you run in-house (like early discovery research) and which parts you hand off to CDMOs and CROs.

Accounting for Hidden Costs

Many founders under-budget for manufacturing because they only look at basic raw material prices. To avoid running out of money, your financial plan must account for hidden operational expenses:

  • Technology Transfer Fees: Moving your lab production process to a CDMO facility takes months of engineering work and testing.
  • Failed Test Batches: Early test batches often fail purity or stability checks, requiring extra capital to re-run.
  • Long-Term Stability Testing: Proving your medicine stays stable for 12 to 24 months in different storage temperatures requires ongoing lab fees.

Before finalizing your operational budget, double-check your expense assumptions against our breakdown of the total cost to build a biotech startup.

💡Tip: Always request formal price quotes from at least two CDMOs. In your plan, present a side-by-side comparison putting the lower-cost vendor right next to the faster-turnaround vendor to show investors you are shopping smartly.

7. Leadership and Advisory Board

This section highlights the track record of your founders, executive team, scientific advisors, and board members. It proves to investors that your team has the hands-on technical and business expertise needed to turn scientific discovery into an approved, commercial product.

Venture capitalists invest in teams first and science second. Early-stage biotech carries high risk, so investors evaluate who came up with the core idea, who leads operational strategy, and whether the leadership team has the clinical experience required to execute your plan.

1. Core Management Team & Founders

Clearly list each core founder and executive member with a focus on past successes:

  • Founder & Chief Executive Officer (CEO): Highlights scientific vision, company leadership experience, and past fundraising or exit history.
  • Chief Scientific Officer (CSO): Focuses on lab discovery track record, patent filings, and target validation experience.
  • Chief Medical Officer (CMO): Details hands-on experience in filing Investigational New Drug (IND) applications, managing FDA communications, or overseeing clinical trial phases.

Give each team member a one-to-two sentence summary highlighting tangible achievements, such as: “Previously led Phase 1/2 clinical trials for an oncology drug at [Company Name] and managed an successful IND filing with the FDA.”

2. Scientific Advisory Board (SAB)

Your Scientific Advisory Board adds academic authority and clinical validation to your business plan:

  • Key Opinion Leaders (KOLs): Prominent medical doctors, clinical researchers, and university professors specializing in your target disease area.
  • SAB Role & Cadence: State explicitly how your advisors support the company—such as reviewing trial protocols twice a year, evaluating preclinical data, or assisting with patient recruitment strategy.

3. Board of Directors & Strategic Advisors

Highlight experienced corporate advisors and early investors who guide corporate governance, help negotiate licensing deals, and provide introductions to venture capital networks.

Addressing Team Gaps Transparently

If no one on your current team has run a multi-center clinical trial or submitted an FDA filing, do not try to hide it. Investors respect founders who recognize operational gaps and present clear hiring plans.

  • Example Hiring Plan Statement: “We are actively recruiting a Chief Medical Officer with Phase 2 oncology trial experience, targeting a key hire within 6 months of closing our Series A round.”

💡Tip: An honest talent gap paired with a clear, budgeted hiring plan builds far more investor trust than a padded team page hiding critical clinical skill gaps.

8. Financial Plan, Valuation and Exit Strategy

This section outlines how much money you need to raise, how you will spend it across clinical milestones, how to calculate your company’s risk-adjusted valuation, and how early investors will make a profit through an exit.

Life science financial models are very different from standard business plans. Early-stage biotech’s spend years with zero product sales, so investors do not expect immediate revenue. Instead, they want to see how efficiently you turn cash into scientific progress.

Milestone-Based Capital Requirements

Never ask investors for money based on vague timelines (like “24 months of operational cash”). In biotech, every single dollar raised must be tied directly to a scientific de-risking milestone—such as finishing animal safety studies, submitting an IND application, or delivering Phase 1 clinical trial data.

According to a comprehensive JAMA drug development cost study, the median cost to bring a new drug to market is $985 million when including the costs of failed attempts. However, your seed or Series A plan only needs to fund your very next development phase:

  • Phase 1 Trial Average Cost: Ranges from $1.4 million to $6.6 million.
  • Phase 2 Trial Average Cost: Ranges from $7.0 million to $19.6 million.
  • Phase 3 Trial Average Cost: Ranges from $11.5 million to $52.9 million.

Real-World Financing Case Study: Catabasis Pharmaceuticals

In a real-world funding example, Catabasis Pharmaceuticals raised a $39.6 million Series A round structured around milestone achievements. The company secured an initial payment to begin early clinical work and drew down a second tranche of $14.5 million only after hitting specific milestone markers toward clinical trial execution. This milestone-based tranche financing protects investors while giving founders clear targets to unlock more capital.

To learn more about structuring your fundraising stages, review our guide on biotech startup funding strategies.

Understanding Risk-Adjusted Valuation (rNPV)

Standard financial valuation models do not work for early biotechs because they ignore scientific failure rates. To fix this, investors use risk-adjusted Net Present Value (rNPV).

According to a 10-year BIO clinical success rates report, the overall chance of a Phase 1 candidate reaching FDA approval is 9.1% for biologics and 5.7% for small molecule drugs.

Simple rNPV Math Example:

  • Suppose your prospective biologic drug candidate is projected to be worth $300 Million after full FDA approval.
  • Since a Phase 1 biologic asset has a 9.1% historical chance of approval, you multiply the target value by the success probability:
  • This means your raw asset value before subtracting ongoing R&D costs is $27.3 Million.

💡Tip: To build these formulas step by step, learn how to forecast revenue for biotech startups in Excel and structure your key biotech financial model components.

Financial Projections, KPIs, and Profit Timelines

Your pro forma financial statements must track R&D expenses, cash burn rate, and runway (how many months of cash remain).

  1. Key Metrics VCs Track: Monitor your quarterly burn rate, trial cost per enrolled patient, and runway to ensure you understand the top 10 biotech startup KPIs for investors.
  2. Realistic Profit Timeline: Be honest with investors about when biotech startups become profitable. Early stage biotech usually stay loss-making for 7 to 10 years until an out-licensing deal closes or clinical trials finish.

Exit Strategy: How Investors Get Paid

Venture capitalists invest in startups to return capital to their limited partners. Your plan must clearly define how early backers will exit their position at a high multiple.

  1. Trade Sale / Big Pharma Acquisition (M&A): The most common exit. A large pharmaceutical firm acquires your startup after positive Phase 1 or Phase 2 clinical data readouts to fill their own drug pipeline.
  2. Out-Licensing & Commercial Partnerships: Selling global or regional licensing rights to a larger partner. The partner pays upfront cash, covers ongoing trial expenses, and pays milestone bonuses while your early investors cash out a portion of their equity.
  3. Initial Public Offering (IPO): Listing your company stock on public stock exchanges (like NASDAQ) once your lead drug candidate reaches late Phase 2 or Phase 3 trials.

💡Tip: Always present your financial plan using three scenarios: a Best Case, a Base Case, and a Worst Case. Investors trust realistic risk ranges far more than a single set of optimistic numbers.

A BIO study of 2011 to 2020 found a 9.1% chance of approval from Phase 1 for biologics and 5.7% for small molecules. If a biologic would be worth $300 million once approved, $300 million times 0.091 gives $27.3 million before costs.

Learn to forecast biotech revenue in Excel, and check each part of a biotech financial model. Show the 10 biotech KPIs investors track and be honest about how long profit really takes. For your exit, name likely buyers, licensing partners, or IPO readiness.

💡Tip: Show a best, base, and worst case. Investors trust ranges more than one number.

Critical Execution Principles for Biotech Plans

To build trust with venture capitalists and avoid common traps, follow these core execution principles:

Strategic Dimension Common Founder Pitfall Winning Approach
Plan Focus
Over-emphasizing academic science and complex laboratory mechanisms.
Structuring your science strictly around commercial value, patient benefits, and clinical de-risking.
Funding Milestones
Requesting capital based purely on time (e.g., asking for “18 months of burn runway”).
Requesting money based on major value-creation events (e.g. funding the path to a “Phase 1 clinical trial data readout”).
Risk Management
Glossing over safety warnings, regulatory hurdles, or manufacturing challenges.
Explicitly mapping out technical and clinical risks alongside concrete, realistic mitigation plans.
Market Sizing
Using lazy top-down claims (e.g. “we plan to capture 1% of the $100B oncology market”).
Calculating rigorous bottom-up market numbers using real disease epidemiology and eligible patient sub-populations.

Common Mistakes Biotech Founders Make

  • Relying on Academic Slide Decks: Venture capitalists want to see a clear commercialization roadmap and a de-risking plan, not a university thesis defense presentation.
  • Ignoring Health Economics: Failing to research whether insurance payers and government healthcare programs will actually reimburse your drug price based on its clinical improvement over existing options.
  • Underestimating Clinical Trial Costs: Budgeting only for basic patient visits while forgetting essential expenses like Contract Research Organization (CRO) management fees, drug logistics, and statistical data analysis.
  • Unrealistic Valuation Claims: Applying tech startup revenue multiples to early-stage, pre-revenue scientific assets without applying proper risk-adjusted Net Present Value (rNPV) probability discounts.
  • Vague Use of Proceeds: Asking for $10 million in funding without providing a precise, milestone-tied budget breakdown across preclinical studies, regulatory filings, and core personnel.

Learning how to write a biotech business plan comes down to one habit: tie every claim, cost, and date to a milestone that makes the company worth more. Draft the summary, fill the gaps pillar by pillar, and test your numbers with an experienced adviser. When you reach the financial section, the biotech financial model and valuation template from Excel Business Resource puts phase costs, runway, and valuation into one file, so you can spend your time on the science instead of the formulas.

Frequently Asked Questions

How long should a biotech business plan be?

Aim for 20 to 30 pages for the full plan, plus a one-to-two-page executive summary. Investors read the summary first and ask for the full plan only if they want to go further. Tie every page to a milestone.

Ask for the amount that reaches your next big milestone, such as an IND filing or first patient data, plus a buffer. Do not size it by months. Many rounds arrive in tranches, as the Catabasis case above shows. Investors then see exactly what their money buys.

A pitch deck is a short slide set that wins a first meeting. A business plan is a 20 to 30 page document that investors read during due diligence. The deck tells the story, and the plan proves it with data, costs, and timelines.

Start with published success rates. A BIO study of 2011 to 2020 found 9.1% for biologics and 5.7% for small molecules from Phase 1 to approval. Then adjust for your disease area and your data, and explain every adjustment.

Most investors want at least a filed application. Without one, they see nothing that protects your work. Show filing dates, countries, and expiry dates. Also get a freedom to operate opinion, because a patent alone does not give you the right to sell.

One JAMA study put the median at $985 million with failures included, but costs vary widely by disease area. Your plan should show costs to your next milestone, and explain how you will fund each phase after it.

Similar Posts